DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Indian markets decline amidst US bond market sell-off and rising yields
23/05/2025
Harvard’s ability to enrol international students halted by Trump administration
22/05/2025
Elon Musk : Politics failed him. Can business redeem him ?
22/05/2025
Goldman Sachs buys shares worth Rs 50 crore in this smallcap stock via block deal
22/05/2025
RBI’s March forex buys hit 5-year high to boost banking liquidity
22/05/2025
Ashok Hinduja backs IndusInd Bank board amid fraud concerns, calls it a 'new dawn' for the lender
22/05/2025
